U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.

Cover of Drugs and Lactation Database (LactMed®)

Drugs and Lactation Database (LactMed®) [Internet].

Show details

Dimethyl Fumarate

Last Revision: September 15, 2024.

Estimated reading time: 3 minutes

CASRN: 624-49-7; 1577222-14-0

image 134977508 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

The active form of both dimethyl fumarate and diroximel fumarate is monomethyl fumarate. Amounts of monomethyl fumarate in breastmilk appear to be low and would not be expected to cause any adverse effects in breastfed infants. Clinical data in over 20 infants indicates that it is acceptable to use during breastfeeding, at least after one month of age. Breastfed infants should be monitored for adequate weight gain and developmental milestones, especially in younger, exclusively breastfed infants. Some authors also recommend monitoring breastfed infants for flushing, vomiting and diarrhea.[1,2]

Drug Levels

Dimethyl fumarate is not found in the plasma because it is rapidly converted to the active drug, monomethyl fumarate, which has a half-life of about 1 hour.

Maternal Levels. Two nursing mothers with relapsing-remitting multiple sclerosis began oral dimethyl fumarate 240 mg twice daily after discontinuing breastfeeding. They continued pumping milk and on day 8 of therapy, they each provided milk samples at 1, 2, 4, 8 and 12 hours after a dose. Peak monomethyl fumarate milk levels were 3.7 mcg/L in one mother and 11.2 mcg/L in the other and occurred at about 2 hours after the dose. Average milk levels were 2.7 mcg/L and 7.5 mcg/L, respectively. These values indicate that the infants would receive daily dosages of about 0.8 mcg/kg and 1.13 mcg/kg, respectively, or weight-adjusted relative infant dosages of 0.007% and 0.019% of the maternal dosage.[2]

A woman with multiple sclerosis who was 3 months postpartum began dimethyl fumarate 120 mg (Polpharma SA Pharmaceutical works, Starogard Gdański, Poland) orally twice daily after weaning her infant. Four milk samples were collected over a 24-hour period 6 days after starting therapy. The concentration of monomethyl fumarate ranged from 83.5 mcg/L just after a dose to undetectable (<5.5 mcg/L) at 2 hours before the next dose. The authors estimated a daily dose of 5.76 mcg/kg with a daily milk intake of 150 mL/kg, which represents a relative infant dose of 0.16%.[3]

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Twenty-six women taking dimethyl fumarate for relapsing-remitting multiple sclerosis were followed during 29 pregnancies from 2015 to 2020. Dimethyl fumarate was administered through week 24 of pregnancy and resumed 1 month after delivery. Twenty-two of 26 mothers breastfed (extent not stated) for 4 to 7 months. Infants were monitored up to the third year of life for infections and developmental disorders. All children were the 70th and 95th percentile for height and weight. The authors concluded that continuing dimethyl fumarate while breastfeeding is safe,[4] although infants were not exposed during the first month of life.

One group reported two mothers with multiple sclerosis who resumed taking dimethyl fumarate 1 week after delivery while partially breastfeeding their infants. One was taking 240 mg daily and withheld breastfeeding for 4 hours after each dose. The other was taking 480 mg daily with mixed feeding continuing for 15 months. The latter patient became pregnant again and once again used mixed feeding while taking dimethyl fumarate. All 3 infants developed normally and had no serious infections.[5]

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Multiple Sclerosis) Glatiramer, Immune Globulin, Interferon Beta

References

1.
Almas S, Vance J, Baker T, et al. Management of multiple sclerosis in the breastfeeding mother. Mult Scler Int 2016;2016:6527458. [PMC free article: PMC4757692] [PubMed: 26966579]
2.
Ciplea AI, Datta P, Rewers-Felkins K, et al. Dimethyl fumarate transfer into human milk. Ther Adv Neurol Disord 2020;13:x. [PMC free article: PMC7607748] [PubMed: 33193814]
3.
Van Neste M, Nauwelaerts N, Ceulemans M, et al. Very low monomethyl fumarate exposure via human milk: A case report—a contribution from the ConcePTION project. Front Public Health 2024;12:1393752. doi:10.3389/fpubh.2024.1393752 [PMC free article: PMC11250615] [PubMed: 39015385] [CrossRef]
4.
Borriello G, Ianniello A. Efficacy, safety and tolerability of dimethylfumarate during pregnancy and breastfeeding. Mult Scler Relat Disord 2022;67:103949. doi:10.1016/j.msard.2022.103951 [CrossRef]
5.
Saito S, Ikeguchi R, Kitagawa K, et al. Clinical experience with dimethyl fumarate and natalizumab in pregnant women with multiple sclerosis: A four-patient case series. Case Rep Neurol Med 2024;2024:7808140. [PMC free article: PMC11265946] [PubMed: 39044765]

Substance Identification

Substance Name

Dimethyl Fumarate

CAS Registry Number

624-49-7; 1577222-14-0

Drug Class

Breast Feeding

Lactation

Milk, Human

Dermatologic Agents

Immunosuppressive Agents

Radiation-Sensitizing Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Copyright Notice

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Bookshelf ID: NBK500735PMID: 29999794

Views

Related information

Similar articles in PubMed

  • Review Diroximel Fumarate.[Drugs and Lactation Database (...]
    Review Diroximel Fumarate.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Carbamazepine.[Drugs and Lactation Database (...]
    Review Carbamazepine.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Mesalamine.[Drugs and Lactation Database (...]
    Review Mesalamine.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Melatonin.[Drugs and Lactation Database (...]
    Review Melatonin.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Ethosuximide.[Drugs and Lactation Database (...]
    Review Ethosuximide.
    . Drugs and Lactation Database (LactMed®). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...